Swapnil Parmar

775 total citations
10 papers, 72 citations indexed

About

Swapnil Parmar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Swapnil Parmar has authored 10 papers receiving a total of 72 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Swapnil Parmar's work include Cancer Genomics and Diagnostics (4 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Swapnil Parmar is often cited by papers focused on Cancer Genomics and Diagnostics (4 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Swapnil Parmar collaborates with scholars based in United States, Japan and South Korea. Swapnil Parmar's co-authors include Annette Kolodzie, Brett Johnson, Zahi Mitri, Gordon B. Mills, Raymond C. Bergan, Jamie M. Keck, Joe W. Gray, Alexander R. Guimarães, Christopher L. Corless and Tomasz M. Beer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Swapnil Parmar

9 papers receiving 72 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Swapnil Parmar United States	5	43	30	22	20	7	10	72
Annette Kolodzie United States	4	35 0.8×	20 0.7×	22 1.0×	17 0.8×	7 1.0×	6	58
Tanya Tupper United States	4	30 0.7×	37 1.2×	20 0.9×	35 1.8×	5 0.7×	5	82
Daphné t’Kint de Roodenbeke Belgium	4	43 1.0×	20 0.7×	15 0.7×	18 0.9×	6 0.9×	7	60
Alexander Andreev-Drakhlin United States	4	32 0.7×	23 0.8×	13 0.6×	20 1.0×	7 1.0×	10	68
Yuanchuang Li China	6	42 1.0×	16 0.5×	14 0.6×	40 2.0×	10 1.4×	7	101
Brian Hanratty United States	6	22 0.5×	52 1.7×	19 0.9×	40 2.0×	7 1.0×	10	89
Cornelia Kolberg-Liedtke Germany	5	58 1.3×	20 0.7×	36 1.6×	23 1.1×	6 0.9×	14	90
E Paris France	2	38 0.9×	44 1.5×	10 0.5×	27 1.4×	4 0.6×	2	77
Jesús Miranda Spain	5	22 0.5×	23 0.8×	26 1.2×	21 1.1×	4 0.6×	12	59
Gustavo Dix Junqueira Pinto Brazil	4	50 1.2×	45 1.5×	28 1.3×	12 0.6×	4 0.6×	5	84

Countries citing papers authored by Swapnil Parmar

Since Specialization

Citations

This map shows the geographic impact of Swapnil Parmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swapnil Parmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swapnil Parmar more than expected).

Fields of papers citing papers by Swapnil Parmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swapnil Parmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swapnil Parmar. The network helps show where Swapnil Parmar may publish in the future.

Co-authorship network of co-authors of Swapnil Parmar

This figure shows the co-authorship network connecting the top 25 collaborators of Swapnil Parmar. A scholar is included among the top collaborators of Swapnil Parmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Swapnil Parmar. Swapnil Parmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Hilton, John, A. Jo Chien, Colombe Chappey, et al.. (2025). Abstract P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results. Clinical Cancer Research. 31(12_Supplement). P4–12. 4 indexed citations

Parmar, Swapnil, et al.. (2024). The Impact of COVID-19 on Medical Education: A Lost Generation of Ophthalmologists?. Cureus.

Guisier, Florian, Jaafar Bennouna, Alexander I. Spira, et al.. (2023). NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 41(16_suppl). TPS8604–TPS8604. 7 indexed citations

Li, Allen, Jamie M. Keck, Swapnil Parmar, et al.. (2021). Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. npj Precision Oncology. 5(1). 28–28. 23 indexed citations

Parmar, Swapnil, Jamie M. Keck, Brett Johnson, et al.. (2021). Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. JCO Precision Oncology. 5(5). 27–32. 1 indexed citations

Mitri, Zahi, Jacqueline Vuky, Kathleen Kemmer, et al.. (2019). A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS1111–TPS1111. 5 indexed citations

Mitri, Zahi, Swapnil Parmar, Brett Johnson, et al.. (2018). Implementing a comprehensive translational oncology platform: from molecular testing to actionability. Journal of Translational Medicine. 16(1). 358–358. 24 indexed citations

Johnson, Brett, Jamie M. Keck, Kiara Siex, et al.. (2018). Abstract 3296: SMMART: Serial measurements of molecular and architectural responses to therapy. Cancer Research. 78(13_Supplement). 3296–3296. 1 indexed citations

Mitri, Zahi, Swapnil Parmar, Brett Johnson, et al.. (2018). Implementing a comprehensive translational oncology platform: From molecular testing to actionability.. Journal of Clinical Oncology. 36(15_suppl). e14521–e14521. 4 indexed citations

10.

Lau, Heather, Swapnil Parmar, Mikhail Kazachkov, et al.. (2016). Enzyme replacement therapy with investigational rhGUS in an infant with non-immune hydrops fetalis and mucopolysaccharidosis type VII. Molecular Genetics and Metabolism. 117(2). S71–S71. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact